Sahajanand Medical Technologies IPO Details: Key Dates, Price Band & Investment Overview

By Wealthova | Last Updated: October 14, 2026

Sahajanand Medical Technologies Limited, a premier research and development-driven medical devices company, is gearing up to make a significant primary market debut with an upcoming ₹475.48 Crore mainboard IPO. Operating with a strategic focus on the high-growth cardiovascular and structural heart segments, the company designs, manufactures, and supplies an extensive portfolio of advanced coronary stents, structural heart devices, and peripheral drug-coated balloons. Empowered by an extensive global sales and marketing network, the company serves healthcare providers across both domestic and international markets. The subscription window for this highly anticipated book-built issue opens on October 15, 2026, and closes on October 19, 2026. The price band is set between ₹327 to ₹344 per equity share. The ₹475.48 Crore offering is structured entirely as an Offer for Sale (OFS) of up to 1.38 Crore shares, with absolutely no Fresh Issue component. Retail investors must apply for a minimum of 1 lot (43 shares), requiring an accessible investment of ₹14,792 at the upper price band. Because the issue is a 100% OFS, the company itself will not receive any fresh capital, and all IPO proceeds will go directly to the selling shareholders. Set to list on both the BSE and NSE platforms, market participants are closely watching this innovative medical technology manufacturer, which reported a robust FY26 total income of ₹1,218.73 Crore alongside a solid net profit of ₹69.08 Crore. Below, we break down the financial health, industry risk factors, and our honest Smart Market Insights to help you decide if you should subscribe to this issue!

Sahajanand Medical Technologies Limited (SMT) is a leading, research-driven global developer and manufacturer of minimally invasive cardiovascular and structural heart devices. Driven by its core mission to make critical healthcare technologies accessible, the company specializes in engineering life-saving medical devices that treat narrowed or blocked blood vessels and structural abnormalities of the heart.

Backed by a formidable intellectual property portfolio containing 119 granted global patents and 78 pending applications, the company's core operational segments include:

• Vascular Intervention Devices: SMT’s largest revenue contributor (accounting for over 61% of its FY26 revenue), featuring advanced drug-eluting coronary stents (such as the flagship Supraflex family) and coronary balloon catheters designed to treat arterial blockages.
• Structural Heart Innovations: The company is rapidly expanding its footprint in structural heart treatments, offering its highly specialized Hydra Transcatheter Aortic Valve Implantation (TAVI) systems and the Cocoon family of septal occluder devices used to close congenital heart defects.
• Peripheral & Renal Solutions: Beyond standard coronary care, SMT develops its own brand of renal stents, peripheral drug-coated balloons, and other critical vascular care products.
• Global Distribution & R&D Network: SMT does not just serve India; it operates a massive international distribution network spanning Europe, Latin America, and Asia, empowered by robust in-house clinical research and advanced manufacturing capabilities that meet strict global regulatory standards.

The ₹475.48 Crore Sahajanand Medical Technologies IPO is structured entirely as a 100% Offer for Sale (OFS) of up to 1.38 Crore equity shares, with absolutely no Fresh Issue component.

Because the public issue is purely an OFS, the company itself will not receive a single rupee from the IPO proceeds to fund its operations or R&D. Instead, all capital raised will be directed toward the following objectives:

• Shareholder Liquidity Exit: The primary purpose of the IPO is to provide a structured liquidity event and exit pathway for the existing promoters and early private equity investors who are offloading their shares to the public market.
• Listing Benefits & Corporate Visibility: By transitioning into a publicly traded entity on the BSE and NSE, SMT aims to significantly enhance its corporate brand image, improve its global visibility among healthcare providers, and establish a public market valuation for its equity shares.